Chediak-Higashi disease is a suspected disease in the field of blood tumors, with complex clinical outcomes and often involving multiple systems. Early identification and standardised clinical care are essential for improving prognosis. The diagnosis of the disease requires a combination of clinical outcomes, imaging checks, laboratory checks and pathological activation.
The platform can help align national and international authorities with teams of experts to provide accurate diagnosis and treatment regimens. In recent years, with the development of treatment-oriented, immune-regulatory therapy and precision medicine, many blood tumor diseases that were previously difficult to treat have been significantly improved. Treatment needs to be closely monitored for efficacy and adverse reactions, adjusted in a timely manner according to the changes in the condition.
Multidisciplinary collaboration (MDT) is particularly important for the comprehensive management of Chediak-Higashi disease. The platform serves the China International Medical Service System, a team of nationally and internationally authoritative experts in the field of blood tumours, who provide the following services to patients: 2. Visiting China: arranging face-to-face treatment with authoritative experts, developing individualized treatment plans; 3.
Full-service: providing one-stop services such as medical translation, medical care, accommodation arrangements; 4. Long-term follow-up: establishing a chronic disease management archive, continuous monitoring of disease changes and treatment effects.